Pfizer has acquired Swiss vaccine company Redvax GmbH in its recent drive to expand the flourishing vaccine business and establish a cure for Herpes 2015. Redvax used to be a part of Redbiotec AG, A Swiss biopharmaceutical company based out of Zurich and Schlieren. The deal is touted to have involved an enormous amount of money but the exact figure was not disclosed to the media.
Redfax is a vaccine developing company that rose into prominence due its contribution to preclinical testing for human cytomegalovirus (CMV). CMV is a virus that has a high rate of occurrence infecting up to 90% of the adult population. The symptoms are almost never expressed so it does not become a concern. However, if the virus is passed on to a child at birth it can cause severe problems like hearing impairment and neurological disorders.
Pfizer has said that it intends to use Redfax’s platform to develop cures for CMV which gives life long problems to more than 5000 children each year. Redfax also has some other undisclosed research operations which has immense potential to give us a better future. Pfizer is head quartered in New York and the scientists at Pfizer have the long term goal of making a vaccine for all diseases.